BDBM601935 4-((3'-oxo-2',3'-dihydro-1'H- spiro[cyclohexane-1,4'- pyrimido[5',4':4,5]pyrrolo[2,1- c][1,2,4]triazin]-7'- yl)amino)benzenesulfonamide::US11643416, Compound 3::US20240150369, Compound 3

SMILES NS(=O)(=O)c1ccc(Nc2ncc3cc4NNC(=O)C5(CCCCC5)n4c3n2)cc1

InChI Key InChIKey=KGJVKYSVVOQPDL-UHFFFAOYSA-N

Data  20 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 20 hits for monomerid = 601935   

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601935(US11643416, Compound 3 | 4-((3'-oxo-2',3'-dihydro-...)
Affinity DataIC50: 2.5nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCyclin-H/Cyclin-dependent kinase 7(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601935(US11643416, Compound 3 | 4-((3'-oxo-2',3'-dihydro-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCyclin-dependent kinase 5 activator 1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601935(US11643416, Compound 3 | 4-((3'-oxo-2',3'-dihydro-...)
Affinity DataIC50: 14nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCyclin-dependent kinase 5 activator 1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601935(US11643416, Compound 3 | 4-((3'-oxo-2',3'-dihydro-...)
Affinity DataIC50: 17nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Targetcdk3cyclin-e(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601935(US11643416, Compound 3 | 4-((3'-oxo-2',3'-dihydro-...)
Affinity DataIC50: 9.90nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCyclin-dependent kinase/G2/mitotic-specific cyclin- 1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601935(US11643416, Compound 3 | 4-((3'-oxo-2',3'-dihydro-...)
Affinity DataIC50: 33nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601935(US11643416, Compound 3 | 4-((3'-oxo-2',3'-dihydro-...)
Affinity DataIC50: 62nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D3(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601935(US11643416, Compound 3 | 4-((3'-oxo-2',3'-dihydro-...)
Affinity DataIC50: 350nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601935(US11643416, Compound 3 | 4-((3'-oxo-2',3'-dihydro-...)
Affinity DataIC50: 130nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601935(US11643416, Compound 3 | 4-((3'-oxo-2',3'-dihydro-...)
Affinity DataIC50: 0.560nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601935(US11643416, Compound 3 | 4-((3'-oxo-2',3'-dihydro-...)
Affinity DataIC50: 2.5nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCyclin-dependent kinase 7(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601935(US11643416, Compound 3 | 4-((3'-oxo-2',3'-dihydro-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601935(US11643416, Compound 3 | 4-((3'-oxo-2',3'-dihydro-...)
Affinity DataIC50: 14nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCyclin-dependent kinase 5 activator 1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601935(US11643416, Compound 3 | 4-((3'-oxo-2',3'-dihydro-...)
Affinity DataIC50: 17nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In DepthDetails
US Patent

Targetcdk3cyclin-e(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601935(US11643416, Compound 3 | 4-((3'-oxo-2',3'-dihydro-...)
Affinity DataIC50: 9.90nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCyclin-dependent kinase 1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601935(US11643416, Compound 3 | 4-((3'-oxo-2',3'-dihydro-...)
Affinity DataIC50: 33nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601935(US11643416, Compound 3 | 4-((3'-oxo-2',3'-dihydro-...)
Affinity DataIC50: 62nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D3(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601935(US11643416, Compound 3 | 4-((3'-oxo-2',3'-dihydro-...)
Affinity DataIC50: 350nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601935(US11643416, Compound 3 | 4-((3'-oxo-2',3'-dihydro-...)
Affinity DataIC50: 130nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601935(US11643416, Compound 3 | 4-((3'-oxo-2',3'-dihydro-...)
Affinity DataIC50: 0.560nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In DepthDetails
US Patent